Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 4/20 | 0.54 |
| ▸ | GRPR | P30550 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 8/20 | 0.53 |
| ▸ | GCGR | P47871 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSH | P09668 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484311 | 0.97 | GLP1R (0.56) | GLP1RGRPRKEAP1NR3C1IL23R | |
| SCHEMBL29484320 | 0.95 | IL23R (0.53) | GLP1RGRPRKEAP1IL23RGCGR | |
| SCHEMBL30208638 | 0.94 | GLP1R (0.57) | GLP1RIL23RGCGRCXCR4 | |
| SCHEMBL29484310 | 0.94 | CTSL (0.53) | GLP1RGRPRKEAP1IL23RCXCR4 | |
| SCHEMBL29484313 | 0.93 | NPBWR1 (0.55) | GLP1RGRPRKEAP1NR3C1IL23R | |
| SCHEMBL31119241 | 0.92 | IL23R (0.53) | GLP1RGRPRKEAP1NR3C1IL23R | |
| SCHEMBL30388309 | 0.92 | IL23R (0.53) | GLP1RGRPRKEAP1IL23RCXCR4 | |
| SCHEMBL30208639 | 0.91 | GLP1R (0.60) | GLP1RIL23RGCGRCXCR4 | |
| SCHEMBL30183034 | 0.91 | GLP1R (0.55) | GLP1RGRPRIL23RCXCR4CTSL | |
| SCHEMBL29670416 | 0.90 | CTSL (0.50) | GLP1RGRPRIL23RCXCR4CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528836-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250282823-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20240285725-A1 | DOSING REGIMENS | SIXTH STREET LENDING PARTNERS | 2024-08-29 | — | — | US | disclosed |
| US-11903994-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230091471-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903994-B2 | Dosing regimens | C3AR1, C1QBP, C9 | GLP1R 320/4885GRPR 383/4885KEAP1 547/4885 |
| US-20240285725-A1 | DOSING REGIMENS | C3AR1, C1QBP, C9 | GLP1R 320/4885GRPR 383/4885KEAP1 547/4885 |
| US-20250282823-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | GLP1R 279/4885GRPR 377/4885KEAP1 1149/4885 |
| US-20230091471-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | GLP1R 283/4885GRPR 377/4885KEAP1 1147/4885 |
| US-12528836-B2 | Dosing regimens | CFD, CFB, VIP | GLP1R 320/4885GRPR 357/4885KEAP1 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.